Liu et al.26 recently found that EHMT2 protected head and neck squamous cell carcinoma cells against cisplatin by increasing GSH expression, suggesting that EHMT2 is a promising target for the prevention of chemotherapy resistance in patients undergoing cancer treatment. Here, EHMT2 is linked to head and neck squamous cell carcinoma.